BAM
FRTX

Brave Asset Management’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Brave Asset Management’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-2
Closed -$6K – 449
2014
Q3 		$6K Hold
2
– – ﹤0.01% 392
2014
Q2 		$6K Hold
2
– – ﹤0.01% 400
2014
Q1 		$6K Hold
2
– – ﹤0.01% 389
2013
Q4 		$6K Buy
+2
New +$7.58K ﹤0.01% 387

Other funds holding FRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
SGAM
Smith Group Asset Management Dallas, Texas $1.96B AUM 43.61% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
SAIG
Semper Augustus Investments Group Highlands Ranch, Colorado $837M AUM 42.35% 1-Year Est. Return

Brave Asset Management's FRTX Position: Q4 2014 in Review

Brave Asset Management sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q4 2014, closing a stake of 2 shares — an estimated $6K sold.

Brave Asset Management first reported a position in FRTX in Q4 2013 and held it in 4 quarters. The position peaked at $6K in Q3 2014. 64 funds tracked by Wall St. Rank hold FRTX as of Q4 2014.

  • Brave Asset Management reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q4 2014 after selling out during the quarter.
  • Brave Asset Management sold 2 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q4 2014, an estimated $6K.
  • Brave Asset Management first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q4 2013 and held it in 4 quarters.
  • Brave Asset Management's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $6K in Q3 2014.
  • 64 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q4 2014.

Based on Brave Asset Management's 13F filing for Q4 2014, filed 2 Feb 2015.